summary
Introduced
01/20/2017
01/20/2017
In Committee
04/27/2017
04/27/2017
Crossed Over
03/07/2017
03/07/2017
Passed
05/04/2017
05/04/2017
Dead
Signed/Enacted/Adopted
07/06/2017
07/06/2017
Introduced Session
2017 Regular Session
Bill Summary
Requires prescribing healthcare providers to adopt and maintain policies for informed consent to opioid therapy in circumstances that carry elevated risk of dependency. Establishes limits for concurrent opioid and benzodiazepine prescriptions. Clarifies Board of Nursing authority to enforce compliance with Uniform Controlled Substances Act. Repeals 6/30/2023. (CD1)
AI Summary
This bill requires prescribing healthcare providers to adopt and maintain policies for an informed consent process between the provider and patient before prescribing opioids in certain high-risk circumstances. It also limits initial concurrent prescriptions for opioids and benzodiazepines to a maximum of seven consecutive days, except for certain medical conditions. The bill clarifies the Board of Nursing's authority to enforce compliance with the Uniform Controlled Substances Act. The provisions of the bill are set to repeal on June 30, 2023.
Committee Categories
Business and Industry, Government Affairs, Health and Social Services
Sponsors (14)
Rosalyn Baker (D)*,
Will Espero (D)*,
Josh Green (D)*,
Les Ihara (D)*,
Lorraine Inouye (D)*,
Michelle Kidani (D)*,
Russell Ruderman (D)*,
Maile Shimabukuro (D)*,
Laura Thielen (D)*,
Jill Tokuda (D)*,
Stanley Chang (D),
Gilbert Keith-Agaran (D),
Donna Kim (D),
Ron Kouchi (D),
Last Action
Act 066, 07/03/2017 (Gov. Msg. No. 1167). (on 07/06/2017)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Loading...